DCP Midstream Partners
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DCP Midstream Partners's revenues will grow 40.5% and EPS will grow 33.3%.
The average estimate for revenue is $543.8 million. On the bottom line, the average EPS estimate is $0.52.
Last quarter, DCP Midstream Partners reported revenue of $330.9 million. GAAP reported sales were 35% lower than the prior-year quarter's $538.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.22. GAAP EPS were -$0.16 for Q3 against $1.35 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 13.4%, 350 basis points better than the prior-year quarter. Operating margin was 0.4%, 1,260 basis points worse than the prior-year quarter. Net margin was -2.7%, 1,410 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.77 billion. The average EPS estimate is $1.66.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 221 members out of 232 rating the stock outperform, and 11 members rating it underperform. Among 76 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 75 give DCP Midstream Partners a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DCP Midstream Partners is outperform, with an average price target of $48.32.
Is DCP Midstream Partners the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
- Add DCP Midstream Partners to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends NxStage Medical. The Motley Fool owns shares of NxStage Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.